Weight-loss Drug Wegovy Cuts Risk of Stroke, Heart Attacks by 20%

Novo Nordisk's obesity drug, Wegovy, reduces the risk of cardiovascular events like heart attack and stroke by 20%.

This marks the first instance of a weight-loss drug displaying medical benefits beyond weight reduction.

The potential for reduced heart risks may increase insurance coverage for the drug.

The clinical trial involved over 17,000 adults with overweight or obesity and existing cardiovascular disease.

The cardiovascular benefits observed could be due to weight loss or other mechanisms in the drug.

Novo Nordisk plans to release more details about the trial in an upcoming earnings call.

Selena Gomez’s Top 5 Billboard Hits

Swipe Up for this story